SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board: 
Last Post: 8/17/2017 8:49:12 PM - Followers: 193 - Board type: Free - Posts Today: 17

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

CVM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM News: Statement of Changes in Beneficial Ownership (4) 05:26 PM
CVM News: Statement of Changes in Beneficial Ownership (4) 05:22 PM
CVM News: Amended Quarterly Report (10-q/a) 08/15/2017 05:11:59 PM
CVM News: Current Report Filing (8-k) 08/15/2017 06:02:23 AM
CVM News: U.S. FDA Removes Clinical Hold on CEL-SCI’s Phase 3 Head & Neck Cancer Trial 08/14/2017 07:00:00 AM
News News Alert: Statement of Changes in Beneficial Ownership (4) 08/17/2017 05:26:33 PM
PostSubject
#8718  Sticky Note Do with this information what you will,... I drkazmd65 09/26/16 01:49:06 PM
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#11893   Cool beans trickledownfacists 08/17/17 08:49:12 PM
#11892   Appreciate that, sinity 08/17/17 08:14:18 PM
#11891   Here is the Jama article with the pics Trustbaby 08/17/17 07:57:52 PM
#11890   Affirm trickledownfacists 08/17/17 04:15:21 PM
#11889   It's obvious that the Navigators V. PharmaNet case sinity 08/17/17 04:10:35 PM
#11888   The photos were in the study when I trickledownfacists 08/17/17 03:45:54 PM
#11887   Nope, if you get your hands on it share. sinity 08/17/17 03:41:35 PM
#11886   In the Jama article , I believe there yankeesnyc27 08/17/17 03:28:48 PM
#11885   http://jamanetwork.com/journals/jamaotolaryngology/fullarticle/483920 Phii MK sinity 08/17/17 02:46:10 PM
#11884   50-100 range. Fund MK & new INDs. No distribution. Geert can't sinity 08/17/17 02:13:22 PM
#11883   What is your best guess as to a yankeesnyc27 08/17/17 01:15:05 PM
#11882   The Arb decision will come in 2-3 weeks sinity 08/17/17 12:49:53 PM
#11881   MONEY IN THE BANK ? yankeesnyc27 08/17/17 11:22:58 AM
#11880   Very interesting recovery over the last 30 or Foxwoods Man 08/17/17 06:19:02 AM
#11879   My strategy is put $200 every time there lightrock 08/17/17 05:22:51 AM
#11878   It makes sense to me though lightrock 08/17/17 01:12:26 AM
#11877   Two letters mailed back in May 2017 sinity 08/17/17 12:15:02 AM
#11876   Quotes taken from: sinity 08/16/17 11:27:45 PM
#11875   Delivery of multiple immune stimulating molecules to the reslabrat 08/16/17 07:50:55 PM
#11874   Same strategy 90% of the investors here had warfaretrader 08/16/17 05:20:59 PM
#11873   Assuming they don't get anything out of arbitration Investorated 08/16/17 04:20:39 PM
#11872   Money in the bank is value to the sinity 08/16/17 04:14:36 PM
#11871   Great find trickledownfacists 08/16/17 03:31:51 PM
#11870   "EXPECTED" = forward looking yankeesnyc27 08/16/17 02:55:48 PM
#11869   This is getting to the point where the Foxwoods Man 08/16/17 02:06:29 PM
#11868   INCR Sec Filing dated 6/30/2017: "The arbitration is currently sinity 08/16/17 02:04:19 PM
#11867   If we get positive arb news price will rise. steve2150 08/16/17 01:56:21 PM
#11866   Well I am making the assumption that they Foxwoods Man 08/16/17 01:48:51 PM
#11865   I agree with you, I think we'll be warfaretrader 08/16/17 12:52:56 PM
#11864   I've been nothing but straight up on this warfaretrader 08/16/17 12:46:45 PM
#11863   thanks , now this is really what i klimanjaro 08/16/17 12:42:18 PM
#11862   umm, its been driven to pennies numerous time's warfaretrader 08/16/17 12:39:10 PM
#11861   How can they release preliminary results if they Trustbaby 08/16/17 12:22:53 PM
#11860   sounds like capitulation sentiment, the more this opinion klimanjaro 08/16/17 12:12:24 PM
#11859   Its not wrong at all, it is what warfaretrader 08/16/17 11:48:49 AM
#11858   This from March 13, 2014 from Seeking Alpha, steve2150 08/16/17 10:56:38 AM
#11857   .10 with hold removed is wrong way wrong sinity 08/16/17 09:57:34 AM
#11856   Agree....and I should add that I remain very Foxwoods Man 08/16/17 09:41:18 AM
#11855   I'm one of those trader's Fox and I warfaretrader 08/16/17 09:37:55 AM
#11854   sinity 08/15/17 11:40:58 PM
#11853   Manipulation takes place everyday in the markets, it's warfaretrader 08/15/17 08:37:10 PM
#11852   https://www.google.com/amp/mobile.reuters.com/article/amp/idUSL2N1730B6 The who sinity 08/15/17 08:14:46 PM
#11851   I've said the two were connected/ joined at warfaretrader 08/15/17 08:13:53 PM
#11850   Trickle this is your post from March 16' "Inventiv sinity 08/15/17 08:01:08 PM
#11849   The Arb imo is a definite win, think sinity 08/15/17 07:30:52 PM
#11848   The hold hit when Arbitration started. Hold ended trickledownfacists 08/15/17 06:33:43 PM
#11847   I would never ever use the word manipulation learning curve 08/15/17 06:27:42 PM
#11846   Probably due to the volatility of the warrants. trickledownfacists 08/15/17 06:16:30 PM
#11845   ETRADE sent me a note that says CVM-WS Turney 08/15/17 06:00:31 PM
#11844   I read that in the original 10-q, so sinity 08/15/17 05:52:11 PM
PostSubject